« Back
Home /
Ruboxistaurin (hydrochloride)

Ruboxistaurin (hydrochloride)

Item no.	HY-10195B-50mg
Manufacturer	MedChem Express
CASRN	169939-93-9
Amount	50 mg
Quantity options	100 mg 10mM*1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitor
Specific against	other
Purity	99.84
Formula	C28H29ClN4O3
Citations	ACS Omega. 2020 Oct 12;5(41):26551-26561.<br/>Biosci Rep. 2018 Sep 7;38(5):BSR20171459.<br/>Cell Biosci. 2021 Feb 8;11(1):32.<br/>Diabetes Metab Syndr Obes. 2019 Nov 4;12:2289-2302.<br/>Endocrinology. 2018 May 1;159(5):2253-2263.<br/>Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.<br/>Acta Pharm Sin B. 2022.<br/>FASEB J. 2024 Mar 31;38(6):e23564.<br/>Trop J Pharm Res. 2022; 21(12): 2508.<br/>[1]Jirousek MR, et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem. 1996;39(14):2664-2671.<br/>[2]Ruboxistaurin: LY 333531. Drugs R D. 2007;8(3):193-199.<br/>[3]Kunt T, et al. The beta-specific protein kinase C inhibitor ruboxistaurin (LY333531) suppresses glucose-induced adhesion of human monocytes to endothelial cells in vitro. J Diabetes Sci Technol. 2007 Nov;1(6):929-35.<br/>[4]Nonaka A, et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2702-6.
Smiles	O=C1NC(C(C2=CN(C3=CC=CC=C32)CCO[C@H](CN(C)C)CC4)=C1C5=CN4C6=CC=CC=C56)=O.[H]Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LY333531 (hydrochloride)
Available
Product Description	Ruboxistaurin (LY333531) hydrochloride is an orally active, selective PKC beta inhibitor (Ki=2 nM). Ruboxistaurin hydrochloride exhibits ATP dependent competitive inhibition of PKC beta I with an IC50 of 4.7 nM. Ruboxistaurin hydrochloride inhibits PKC beta II with an IC50 of 5.9 nM[1][2].
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	Metabolism-sugar/lipid metabolism
MolecularWeight	505.01
Clinical Information	Launched
Manufacturers Research Area	Metabolic Disease
Solubility	DMSO : 6.67 mg/mL (ultrasonic)
Target	PKC
Manufacturers Target	PKC
Isoform	PKCα; PKCβ; PKCγ; PKCδ; PKCε; PKCη
Manufacturers Pathway	Epigenetics; TGF-beta/Smad
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10195B-50mg-safety-datasheet.pdf